what is microdosing glp 1 dose GLP-1: A New Approach to Inflammation-Driven Diseases GLP-1 Microdosing 2026: 0.1mg Chart

Jacquet A, Grolleau A, Jove J, Lassalle R, Moore N

GLP-1, or Glucagon-like Peptide-1, is a hormone produced in the gut, specifically by the L cells of the small intestine and colon

Most evidence comes from standard therapeutic doses used for diabetes or obesity management

This triggers a Medicare funding warning which legally requires the President to submit a proposal to Congress to reduce that dependency

When the Breakthrough Obesity G-Agonist Drugs Exceed Expectations The expanding GLP-1 family of drugs and their expanded potential use cases Back last December I wrote about the The New Obesity Breakthrough Drugs, and specifically the striking results in randomized trials for semaglutide (Wegovy) and tirzepatide (Mounjaro) for weight loss, their putative mechanism(s), while also emphasizing their very high cost, lack of plan for successful weaning, and exacerbation of health inequities

Mounjaro: Mounjaro contains tirzepatide, the first dual GIP and GLP-1 receptor agonist